Peanut Oral Immunotherapy With or Without H and H Antihistamine Premedication for Peanut Allergy (PISCES): A Placebo-Controlled Randomized Clinical Trial.

Background: Current forms of peanut oral immunotherapy (OIT) are associated with side effects, and there is a lack of evidence addressing how to mitigate them.

Objective: To determine whether premedication with desloratadine and ranitidine results in fewer side effects during peanut OIT/desensitization.

Methods: A total of 43 patients with peanut allergy (mean age, 7.

Prediction of clinical peanut allergy status among children in Hamilton, Ontario using chart review data collected during 2012-2015.

Background: Peanut sensitization does not necessarily indicate clinical peanut allergy, and uncertainty as to whether or not there is true peanut allergy can lead to increased anxiety and decreased quality of life for patients and their families. The gold standard for diagnosing clinical peanut allergy is the oral food challenge, but this method is time-consuming and can cause severe allergic reactions. It would therefore be beneficial to develop a tool for predicting clinical peanut allergy in peanut-sensitized individuals whose peanut allergy status is unknown so as to better determine who requires an oral food challenge for diagnosis.